Skip to main content
Log in

α2‐Adrenergic effect on human breast cancer MCF‐7 cells

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

(-)Epinephrine (Epi) and –Norepinephrine (NEpi) significantly stimulated tritiated Thymidine incorporation in MCF‐7 cells at concentrations 10–30 pM to 10 nM, with an EC50 of 10 pM for Epi and 14.2 pM for NEpi. To characterize this action, cells were incubated in the presence of NEpi or Epi and different antagonists. The β‐adrenergic antagonist Propanolol showed no effect on the agonist's stimulation, whereas the α‐adrenergic antagonist Phentolamine, reverted it completely at high concentrations (100 μM). The α1‐adrenergic antagonist Prazosin (Pra) acted only at high concentrations, while the α2‐adrenergic antagonist Yohimbine (Yo) reverted the stimulation at an EC50 of 0.11μM. Likewise, when the cells were incubated in the presence of the specific α2‐adrenergic agonist Clonidine (Clo), Thymidine incorporation was significantly stimulated at an EC50 of 0.298 pM. Again, the incubation of the cells in the presence of the α1‐adrenergic antagonist Pra exerted its action at high concentrations, whereas the α2‐adrenergic antagonist Yo showed a clear reversal of the agonist's enhancement at an EC50 of 0.136 μM.

Moreover, Clo caused a clear and significant inhibition of stimulated cAMP levels both in the intracellular and the extracellular fractions. Yo showed a complete reversion of cAMP levels to control values in the presence of Clo, while Pra had the opposite effect. These data suggest that the stimulation provoked in Thymidine incorporation by the agonists Epi, NEpi, and Clo is, at least in part, due to an α2‐adrenergic mechanism directly on tumoral cells, and that the effect is coupled with inhibition of cAMP levels, as described for this kind of receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

References

  1. Mor V, Malin M, Allen S: Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr 16: 191–197, 1994

    Google Scholar 

  2. Hilakivi-Clarke L, Rowland J, Clarke R, Lippman ME: Psychosocial factors in the development and progression of breast cancer. Breast Cancer Res Treat 29: 141–160, 1993

    Google Scholar 

  3. Forsén A: Psychosocial stress as a risk for breast cancer. Psychother Psychosom 55: 176–185, 1991

    Google Scholar 

  4. Cooper CL, Faragher EB: Psychosocial stress and breast cancer: the inter-relationship between stress events, coping strategies and personality. Psychol Med 23: 653–662, 1993

    Google Scholar 

  5. Tross S, Herndon J, Korzun A, Kornblith AB, Cella DF, Holland JF, Raich P, Johnson A, Kiang DT, Perloff M, Norton L, Wood W, Holland JC: Psychological symptoms and diseasefree and overall survival in women with stage II breast cancer. JNCI 88: 661–667, 1996

    Google Scholar 

  6. Vogel WH: Coping, stress, stressors and health consequences. Neuropsychobiology 13: 129–135, 1985

    Google Scholar 

  7. Rose RM: Psychoendocrinology. In: Wilson JD, Foster DW (eds) Williams Textbook of Endocrinology, 7th edition. W.B. Saunders, Philadelphia, 1985, pp 653–681

    Google Scholar 

  8. Vendewalle B, Revillion F, Lefebvre J: Functional b-adrenergic receptors in breast cancer cells. J Cancer Res Clin Oncol 116: 303–306, 1990

    Google Scholar 

  9. Marchetti B, Spinola PG, Plante M, Poyet P, Follea N, Pelletier G, Labrie F: Beta-adrenergic receptors in DMBA-induced rat mammary tumors: correlation with progesterone receptor and tumor growth. Breast Cancer Res Treat 13: 251–263, 1989

    Google Scholar 

  10. Hammon HM, Bruckmaier RM, Honegger UE, Blum JW: Distribution and density of a-and b-adrenergic receptor binding sites in the bovine mammary gland. J Dairy Res 61: 47–57, 1994

    Google Scholar 

  11. Berthois Y, Katzenellenbogen JA, Katzenellenbogen B: Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci 83: 2496–2500, 1986

    Google Scholar 

  12. Del Punta K, Charreau EH, Pignataro OP: Nitric oxide inhibits Leydig cell steroidogenesis. Endocrinology 137: 5337–5343, 1996

    Google Scholar 

  13. Birnbaumer L: Techniques in cyclic nucleotide research. In: Schrader WT, O'Malley BW (eds) Laboratory Methods Manual for Hormone Action and Molecular Endocrinology, 4th edition, Chap 9. Depart. Cell Biology, Baylor College of Medicine, Houston, TX, pp 9–16

  14. Dowdy S, Wearden S: Statistics for Research. Wiley, New York, 1983, pp 243–286

    Google Scholar 

  15. Black PH: Minireviews: Central nervous system – immune system interactions: psychoneuroendocrinology of stress and its immune consequences. Antimicrob Agents Chemother 38: 1–6, 1994

    Google Scholar 

  16. Benschop RJ, Nieuwenhuis EES, Tromp EAM, Godaert GLR, Ballieux RE, van Doornen LJP: Effects of b-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation 89: 762–769, 1994

    Google Scholar 

  17. Lippman ME, Bolan G, Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595–4601, 1976

    Google Scholar 

  18. MacDonald E, Kobilka BK, Scheinin M: Gene targeting– homing in on a2-adrenoceptor-subtype functions. TIPS 18: 211–219, 1997

    Google Scholar 

  19. Aronica SM, Katzenellenbogen BS: Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol 7: 743–752, 1993

    Google Scholar 

  20. Ruffolo RR, Nichols AJ, Stadel JM, Hieble JP: Structure and function of a-adreno-ceptors. Pharmacol Rev 43: 475–505, 1991

    Google Scholar 

  21. Fontana JA, Miksis G, Miranda DM, Durham JP: Inhibition of human mammary carcinoma cell proliferation by retinoids and intracellular cAMP-elevating compounds. JNCI 78: 1107–1112, 1987

    Google Scholar 

  22. Kapoor CL, Grantham F, Cho-Chung YS: Nucleolar accumulation of cyclic adenosine 30: 50-monophosphate receptor proteins during regression of MCF-7 human breast tumor. Cancer Res 44: 3554–3560, 1984

    Google Scholar 

  23. Bøe R, Gjertsen BT, Døskeland SO, Vintermyr OK: 8-ChlorocAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line. Br J Cancer 72: 1151–1158, 1995

    Google Scholar 

  24. Alblas J, van Corven EJ, Hordijk PL, Milligan G, Moolenaar WH: Gi-mediated activation of the p21ras-mitogen-activated a2-Adrenergic effect on MCF-7 cells. 49 protein kinase pathway by a2-adrenergic receptors expressed in fibroblasts. J Biol Chem 268: 22235–22238, 1993

    Google Scholar 

  25. van Blesen T, Hawes BE, Luttrell DK, Krueger KM, Touhara K, Porfiri E, Sakaue M, Luttrell LM, Lefkowitz RJ: Receptortyrosine-kinase-and Gbg-mediated MAP kinase activation by a common signaling pathway. Nature 376: 781–784, 1995

    Google Scholar 

  26. Cacioppo JT: Social neuroscience: autonomic, neuroendocrine, and immune responses to stress. Psychophysiology 31: 113–128, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vázquez, S.M., Pignataro, O. & Luthy, I.A. α2‐Adrenergic effect on human breast cancer MCF‐7 cells. Breast Cancer Res Treat 55, 41–49 (1999). https://doi.org/10.1023/A:1006196308001

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006196308001

Navigation